Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Sun Pharmaceutical Industries Ltd
| Q2 FY26 Earnings Call Transcript
Summary : Sun Pharma reported strong Q2 FY26 growth in Innovative Medicines and India, with US generics declining, while investing in R&D and preparing for key product launches amidst market uncertainties.
Management Perspective positive : Management highlighted strong growth in Global Innovative Medicines (16.4%) and India (11%), expressed excitement about the GLP-1 market, and affirmed a strong balance sheet. They anticipate continued growth for key innovative products like ILUMYA and CEQUA.
Concall Report Analysis & Insights
Business Overview
- Q2 FY26 consolidated sales grew 8.6% year-over-year to INR144,052 million.
- Gross margin was 79.3%, with EBITDA increasing 14.9% to INR45,271 million.
- Global Innovative Medicines sales rose 16.4% to USD313 million, surpassing US generics.
- India formulation sales grew 11% to INR47,348 million, holding 8.3% market share.
- US business declined 4.1% to $496 million due to generics competition and lower lenalidomide sales.
Future Growth Prospects
- Anticipate continued growth for ILUMYA in psoriasis market and potential psoriatic arthritis sBLA filing.
- Expect improved access and uptake for newly launched LEQSELVI in the US.
- Planning to launch UNLOXCYT in the US during the second half of FY '26.
- Investing in R&D pipeline for Innovative Medicines, with 38% of total R&D spend allocated.
- Aim to participate in the exciting and growing GLP-1 market with competitive products.
Management Insights
- Q2 FY26 showed strong financial performance with significant growth in Innovative Medicines and India.
- Balance sheet remains strong with $2.9 billion net cash after acquisitions and settlements.
- US Innovative Medicine sales surpassed generics for the first time, a strategic shift.
- R&D spend for FY '26 is expected to be at the lower end of the 6%-8% guidance.
- Committed to growing both Innovative Medicines and Generics businesses globally.
Signs of Skepticism
- US generics business declined, with no clear strategy articulated to reverse this trend.
- Uncertainty remains regarding the impact of potential US tariffs on innovative products.
- R&D spend is tracking below guidance, suggesting potential delays or reduced investment in pipeline.
- Specific timelines for semaglutide approval in Canada were not disclosed.
- Cash flow declined year-over-year despite similar profits, attributed to working capital and acquisitions.
Risk Factors
- US generics business faces decline due to increased competition and lower lenalidomide sales.
- Uncertainty regarding potential US tariffs on patent drug imports and Section 232 investigation.
- Increased effective tax rate (ETR) expected to hover around 25% as past benefits expire.
- Competition in the alopecia areata market could hinder growth for targeted treatments like Leqselvi.
- Cash flow impacted by working capital changes, business acquisitions, and settlements.
Good To Know
- Effective tax rate for Q2 FY26 was 24.7%, up from 15.8% in Q2 FY25.
- Net cash position is $2.9 billion, even after Checkpoint acquisition and GxMDL settlement.
- ILUMYA is commercialized in 35 major markets globally.
- Company launched 9 new products in India during Q2 FY '26.
- Consolidated R&D investments for Q2 FY '26 were INR7,827 million, or 5.4% of sales.
Key Drivers
- ILUMYA sales growth in 35 markets.
- Upcoming US launch of UNLOXCYT.
- New product launches in India.
- Entry into growing GLP-1 market.
Key Analyst Discussions
Competitive Environment
- New competition for Restasis is expected to primarily impact Restasis, not Cequa pricing or growth.
- ILUMYA continues to grow despite competition in the IL-23 and overall psoriasis markets.
- Leqselvi market is expected to grow, with new prescribers adopting JAK inhibitors for alopecia areata.
- Sun Pharma aims to be competitive in the GLP-1 market, launching products when patent exclusivity ends.
- ODOMZO holds over 50% market share among dermatologists in the US for basal cell carcinoma.
Market Trends & Consumer Behavior
- India's formulation sales growth was volume-led, unlike IPM which is price-led.
- GLP-1 market is considered very exciting and expected to continue growing.
- Psoriasis market and IL-23 market continue to grow, supporting ILUMYA's momentum.
- Penetration of targeted treatments for alopecia areata is low but expected to grow.
- Emerging Markets and ROW growth driven by both Generics and Innovative Medicines.
Financial Highlights
- Intangible assets increased due to Checkpoint acquisition ($471 million) and Leqselvi-related assets ($300 million).
- Specialty spend for Leqselvi and Unloxcyt launches increased in Q2, with further increases expected in Q3/Q4.
- Generic lenalidomide sales were flat quarter-over-quarter, with a year-over-year drop.
- Cash flow declined due to increased working capital, business acquisitions, and GxMDL settlement.
- Short-term borrowings for acquisitions are expected to reduce over time.
Product Composition
- US Innovative Medicine sales surpassed generics for the first time in Q2 FY26.
- Strategy is to grow both Innovative Medicines and Generics businesses.
- ROW growth was led by both Generics and Innovative Medicines, particularly ILUMYA and ODOMZO.
- ILUMYA is a strong franchise for ex-US growth, launched in 35 countries.
- Semaglutide product will be a pen product to remain competitive.
Strategic Considerations
- Company is studying FDA guidance on biosimilars before finalizing US/Europe strategy.
- Considering expanding US manufacturing footprint in due time, already have a presence.
- Compiling dossier for cosibelimab for European markets.
- GL0034 (GLP-1 compound) Phase II study for type 2 diabetes to start shortly.
- Fibromun Phase II/III data for soft tissue sarcoma and glioblastoma are yet to be released.